# Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

> **NCT04290793** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 113 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pyrotinib
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Taxanes
- **BIOLOGICAL:** Trastuzumab

## Key facts

- **NCT ID:** NCT04290793
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-10
- **Target enrollment:** 113 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04290793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04290793, "Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04290793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*